BROVAR
(Breast and Ovarian Cancer)
qPCR SNP Detection Kit
Description
These genes code a protein responsible for inhibiting tumor growth by participating in DNA repair mechanisms. Mutations in the gene lead to the formation of cancer cells. The genetic burden associated with abnormalities in the indicated genes significantly increases the risk of breast and ovarian cancer, and is also hereditary.
REF. NUMBER
755SNP451pbc
PREDISPOSITION
Breast and Ovarian Cancer
ANALYSED GENES
BRCA1, BRCA2
IDENTIFIED POLYMORPHISMS
rs80357906, rs28897672, rs80357711, rs80357914, rs80359550
KIT CONTENTS
5 × Nuclease-Free Water
5 × 2xSNP MasterMix
5 × Oligos Set
5 × Positive Control Set
QUANTITY
100 rxns
STORAGE CONDITIONS
-25°C to -15°C
CERTIFICATES
More Information
Did you know...?
According to WHO, in the European Region, breast cancer is the most common cancer and the leading cause of cancer death amongst women. The latest statistics from 2020 show that 576 337 women in Europe were diagnosed with breast cancer and 157 111 died from the disease. WHO data says that at the end of 2020 there were 2.3 milion women alive, diagnosed with breast cancer in the previous 5 years. Due to the high frequenency of breast and ovarian cancer incidence it is important to be aware of the risk of these diseases.
What may happen?
Genetic predisposition to breast or ovarian cancer strongly influences the incidence of these cancers. The BRCA1 and BRCA2 genes play a key role in cancer development. Changes in these genes result in loss of proteins function which can lead to development of disease. A mutation in BRCA1/2 leads to a lifetime likelihood of breast cancer of over 80%. There is a 70% risk of developing breast cancer before the age 70 and 59% before the age 50 if the mutation occurs in BRCA1. Risk of developing ovarian cancer in BRCA1 mutation is 40% before the age 70 and 16% before the age of 50. If mutation occurs in BRCA2 gene, the risk of developing breast cancer is 56% and ovarian cancer 27%. Moreover BRCA2 mutation increases the risk of other types of cancers: colon cancer and pancreatic cancer for both men and women.
How the test is performed?
In the offered package of genetic predispositions based on the analysis of polymorphisms we mark BRCA1 and BRCA2 genes. The offered test informs the patient about their genetic polymorphisms without the time consuming need to sequence the genetic material. Fast and precise real-time PCR test is used for gene analysis.
How will the client benefit?
The technique used allows for efficient determination of the patient’s genotype in a short time and thus determining the risk of the disease. The preparation of the reaction mixture is simple and requires a small a quantity of reagents. Identical thermal cycling profiles of some BRCA1 gene polymorphisms allow simultaneous analysis, which speeds up the result. An additional advantage is the uncomplicated analysis of the obtained data which compares the sample’s signals with the matrix presented in the IFU.
Why is it worth doing a genetic test?
Thanks to education on the genetic background in the development of breast and ovarian cancer, these studies are gaining more and more acceptance. Professional service and a report with a comprehensive explanation of the result and recommendations will encourage the patient to use other genetic tests. This is particularly important in the case of diseases such as breast and ovarian cancer, in which early diagnosis gives a chance for effective treatment.
What can be done after the test result?
In the case of an unfavorable variant of the gene, it is important to follow the recommendations and consult IVD a doctor. It should be remembered that a normal genotype does not exclude the disease. The great potential of genetic testing makes it possible to predict many diseases and provides the patient with an opportunity to take action to improve their health.